tegobuvir
Small moleculeexperimental
Clinical trial activity
7 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
7
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2008 (NCT00743795)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- RNA-directed RNA polymeraseINHIBITOR
RNA-directed RNA polymerase inhibitor
Covalent inhibitor
- Genome polyproteinINHIBITOR
Genome polyprotein inhibitor
Hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitor
Covalent inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Fc1ccccc1-c1nc2ccn(Cc3ccc(-c4ccc(C(F)(F)F)cc4C(F)(F)F)nn3)cc-2n1- Mol. weight
- 517.41 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1957287 ↗
Also known as
- gs-9190
- gs-9190
- gs-9190
- tegobuvir
- tegobuvir
- tegobuvir
- tegobuvir
- tegobuvir
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01434498 | Phase 2 | Sep 1, 2011 | Gilead Sciences |
| NCT01435226 | Phase 2 | Sep 1, 2011 | Gilead Sciences |
| NCT01353248 | Phase 2 | May 1, 2011 | Gilead Sciences |
| NCT01271790 | Phase 2 | Oct 1, 2010 | Gilead Sciences |
| NCT01225380 | Phase 2 | Oct 1, 2010 | Gilead Sciences |
| NCT01072695 | Phase 2 | Feb 1, 2010 | Gilead Sciences |
| NCT00743795 | Phase 2 | Oct 1, 2008 | Gilead Sciences |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gilead Sciences | For profit | 7 | 7 | 1 | 2008 |
1 organizations
Page 1 / 1